Travoprost Oil
NDC Package 54893-0020-6

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Travoprost oils is travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (e.g., ocular hypertension). This formulation utilizes a oil delivery system. Marketed by Msn Laboratories Private Limited, this product is identified by NDC 54893-0020.

Identification & Billing

NDC Package Code
54893-0020-6
Package Description
3 kg in 1 DRUM
Product Code
54893-0020
11-Digit Billing Format
54893002006

Clinical Specifications

Proprietary Name
Travoprost
Non-Proprietary Name
Travoprost
Substance Name
Travoprost
Dosage Form
Oil - An unctuous, combustible substance which is liquid, or easily liquefiable, on warming, and is soluble in ether but insoluble in water. Such substances, depending on their origin, are classified as animal, mineral, or vegetable oils.
Active Ingredient(s)
TRAVOPROST 1 kg/kg
Usage Information
Travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (e.g., ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Regulatory & Marketing

Labeler Name
Msn Laboratories Private Limited
Product Type
Bulk Ingredient
Marketing Category
BULK INGREDIENT - A category specifying that a product is marketed as a bulk ingredient.
Start Marketing Date
01-31-2014
Listing Expiration
12-31-2027
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 54893-0020-6 identifies a specific commercial package of 3 kg in 1 drum of Travoprost (UNFINISHED drug), a bulk ingredient labeled by Msn Laboratories Private Limited. This oil is formulated for use and contains travoprost as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Msn Laboratories Private Limited on January 31, 2014. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (e.g., ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

How is this Msn Laboratories Private Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 54893002006. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
54893-0020-6
11-Digit CMS (5-4-2)
54893-0020-06

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.